TY - JOUR T1 - A Case of Disseminated Cutaneous <em>Mycobacterium chelonae</em> Infection During Treatment With Tofacitinib JF - The Journal of Rheumatology JO - J Rheumatol DO - 10.3899/jrheum.200730 SP - jrheum.200730 AU - Vinit Joseph Gilvaz AU - Elinor Mody AU - Saud Abaalkhail Y1 - 2021/07/01 UR - http://www.jrheum.org/content/early/2021/06/24/jrheum.200730.abstract N2 - Janus kinase ( JAK) inhibitors, like other immunomodulators, are known to be associated with an increased risk of infections.1 An analysis of long-term clinical trial data has shown tuberculosis to be the most common opportunistic infection associated with tofacitinib use.2 ER -